In order to solve the problem of rapid inactivation of GLP-1 by DPP-4 degradation, GLP-1RAs and DPP-4 inhibitors have been developed to treat T2DM (Kim and Jang, 2015; Böhm et al., 2017). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.